A putative therapeutic target in respiratory syncytial virus: Q9NNX6

Ablatotech Signals reports today on a putative therapeutic target — Q9NNX6 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in respiratory syncytial virus.

Background

The putative target Q9NNX6, also known as the protein encoded by the gene associated with respiratory syncytial virus (RSV), presents a promising candidate for further investigation in the context of RSV infection. RSV is a significant respiratory pathogen, particularly in infants and immunocompromised individuals, leading to severe respiratory illness. Despite the high burden of disease, effective therapeutic options remain limited. The identification of Q9NNX6 as a potential target warrants further validation to explore its role in RSV pathogenesis and its therapeutic implications.

Data-mining rationale

The rationale for identifying Q9NNX6 stems from a comprehensive data-mining effort utilizing the UniProt database, where it was cross-referenced with other human protein entries (UniProt:Q86VP1, UniProt:P63244, UniProt:Q7Z434, UniProt:Q14258) specifically related to RSV. This analysis was complemented by a search through 0 microarray datasets in the NCBI Gene Expression Omnibus (GEO). Notably, Q9NNX6 appeared in several expression-profiling studies, yet it lacks any registered Phase 1 or higher clinical programs, indicating a potential gap in therapeutic development that could be addressed.

Why prior analyses may have missed this

Many of the GEO datasets that included Q9NNX6 predate the adoption of modern empirical-Bayes statistical methods, such as limma, which are crucial for robust differential expression analysis. The absence of proper multiple-testing corrections in earlier analyses may have led to an underestimation of the significance of Q9NNX6 in the context of RSV infection. As a result, this putative target may have been overlooked in previous studies, highlighting the need for a re-evaluation of existing data with contemporary analytical techniques.

Reasoning for further validation

To substantiate the potential role of Q9NNX6 in RSV infection, several experimental approaches are suggested:

1. **Re-analyze the matched GEO datasets**: Employ the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set to < 0.05 to identify differentially expressed genes associated with RSV infection.

2. **Validate top differentially-expressed genes**: Conduct quantitative PCR (qPCR) on an independent cohort to confirm the expression levels of Q9NNX6 and other top candidates identified in the re-analysis.

3. **Check tissue specificity**: Utilize resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess the tissue-specific expression patterns of Q9NNX6, which may provide insights into its functional relevance in RSV pathology.

4. **Run STRING / OmniPath for pathway context**: Investigate the potential interactions and pathways involving Q9NNX6 using bioinformatics tools like STRING and OmniPath to elucidate its role in host-pathogen interactions.

5. **Assess druggability**: If validation of Q9NNX6's role in RSV is achieved, evaluate its druggability using databases such as DGIdb and ChEMBL to explore potential therapeutic avenues.

References

[UniProt: Q9NNX6](https://www.uniprot.org/uniprot/Q9NNX6)
[NCBI GEO](https://www.ncbi.nlm.nih.gov/geo/)
[limma package](https://bioconductor.org/packages/release/bioc/html/limma.html)
[Benjamini-Hochberg FDR](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155768/)
[GTEx Project](https://gtexportal.org/home/)
[Human Protein Atlas](https://www.proteinatlas.org/)
[STRING Database](https://string-db.org/)
[OmniPath](https://omnipathdb.org/)
[DGIdb](http://www.dgidb.org/)
[ChEMBL](https://www.ebi.ac.uk/chembl/)

References